Citation

Hacimusalar Y, Esel E. Noro Psikiyatr Ars 2018; 55(3): 280-290.

Affiliation

Department of Psychiatry, Erciyes University Faculty of Medicine, Kayseri, Turkey.

Copyright

(Copyright © 2018, Turk Noro-Psikiyatri Derneginin Yayin Organidir)

DOI

10.5152/npa.2017.19482

PMID

30224877

PMCID

PMC6138223

Abstract

Currently, the diagnosis of major depressive disorder (MDD) mainly relies on clinical examination and subjective evaluation of depressive symptoms. There is no non-invasive, quantitative test available today for the diagnosis of MDD. In MDD, exploration of biomarkers will be helpful in diagnosing the disorder as well as in choosing a treatment, and predicting the treatment response. In this article, it is aimed to review the findings of suggested biomarkers such as growth factors, cytokines and other inflammatory markers, oxidative stress markers, endocrine markers, energy balance hormones, genetic and epigenetic features, and neuroimaging in MDD and to evaluate how these findings contribute to the pathophysiology of MDD, the prediction of treatment response, severity of the disorder, and identification of subtypes. Among these, the findings related to the brain-derived neurotrophic factor, the hypothalamo-pituitary-adrenal axis, cytokines, and neuroimaging may be strong candidates for being biomarkers MDD, and may provide critical information in understanding biological etiology of depression. Although the findings are not sufficient yet, we think that the results of epigenetic studies will also provide very important contributions to the biomarker research in MDD. The availability of biomarkers in MDD will be an advancement that will facilitate the diagnosis of the disorder, treatment choices in the early stages, and prediction of the course of the disorder.

Language: en

Keywords

Depression; biomarkers; brain-derived neurotrophic factor; cytokines; genetics; neuroimaging